1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Chronic Kidney Disease (CKD) Drugs Industry: Forecasts to 2024

  • March 2017
  • 143 pages
  • ID: 4826703
In this report:
Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents (ESAs), and Diuretics; End User - Hospitals and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Summary

Table of Contents

Chronic Kidney Disease Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents, and Diuretics; End User - Hospitals and Specialty Clinics) - Global Industry Analysis, Size, Share, Increase, Forecasts, and Forecast 2016 - 2024

Global Chronic Kidney Disease Drugs Market: Summary

This industry report on the overall chronic kidney disease drugs market examines the current and future prospects of the market. The study comprises a detailed executive summary, containing a market snapshot that offers global information of several segments and subsegments. The industry research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts together with info collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and different worldwide and national databases. The analysis offers market value in terms of US$ Mn for each division for the time span from 2014 to 2024, examining the macro and micro environmental factors. Growth rates for each section within the overall chronic kidney disease drugs market have been determined after a thorough analysis of past trends, demographics, next trends, technological developments, and regulatory requirements.

A in-depth qualitative analysis of factors responsible for driving and restraining market increase and future opportunities has been specified in the market survey part. This section of the report also provide business insights into the top trends of the chronic kidney disease drugs market including novel treatment approaches including monoclonal antibodies, RNA-based therapies and stem cell based therapies. The main market indicators influencing overall Chronic Kidney Disease Drugs market taken into consideration including cost constraints and regulatory landscape. The market research also comprises Analysis of market appeal of the main segments that offers a comprehensive study of the overall competitive scenario in the global Chronic Kidney Disease Drugs market. The industry report also accentuates top events of the overall Chronic Kidney Disease Drugs industry. A porter's five force analysis highlighting opposing landscape is also included in the study.

Market income in terms of US$ Mn for the time between 2014 and 2024 along with the CAGR from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of overall Chronic Kidney Disease Drugs market for each division is also reflected. On top of, market related factors including growing preference for product innovation, and cost reduction for hospitals and greater affordability for patients in several geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Chronic Kidney Disease Drugs Market: Segmentation

Established on product class, the overall Chronic Kidney Disease Drugs market has been divided into ACE Inhibitors, Angiotensin-II receptor blockers, Calcium channel blockers, Beta blockers, Erythropoiesis-stimulating agents, Diuretics, and Others. Established on consuemr, the sector has been broken down into hospitals and specialty clinics. Hospitals segment is forecast to remain dominant during the forecast period.

Geographically, the overall Chronic Kidney Disease Drugs market has been split into five regions: North America continent, Europe (EU), Asia Pacific (APAC), Latin America area, and Middle East (ME) & African continent. Additionally, the areas have been farther divided into main countries from each area. These include the U.S.A, Canada (CA), the United Kingdom, Germany (DE), France (FR), Italy (IT), Spain (ES), China (CN), Australia (AU), India (IN), Japan (JP), Brazil (BR), and Mexico (MX).

Global Chronic Kidney Disease Drugs Market: Opposing landscape

The study also describes main actors in the Chronic Kidney Disease Drugs segment based on several features such as corporate overview and financial analysis, SWOT study, main business strategies, product portfolio, and recent evolutions. A thorough market share analysis of main companies operating in the Chronic Kidney Disease Drugs market is specified in the analysis. Key companies decribed in the market research contain Keryx Biopharmaceuticals, Incorporated, Kissei Pharmaceutical Co., Ltd, AbbVie, Incorporated, GlaxoSmithKline plc., Sanofi S.A. , F. Hoffmann-La Roche Ltd., Pfizer, Incorporated, AstraZeneca plc, Amgen Inc., and Teva Pharmaceutical Industries Ltd.

By Geography

North America (NA)

USA

Canada (CA)

Europe (EU)

United Kingdom (UK)

Germany (DE)

France (FR)

Spain (ES)

Italy (IT)

Rest of europe (EU)

Asia-Pac

China (CN)

Japan (JP)

Australia (AU)

India (IN)

Rest of Asia Pacific (APAC)

Latin America

Brazil (BR)

Mexico (MX)

Rest of Latin America

African region & Middle East

South africa (SA)

Saudi arabia (SA)

Rest of African region and Middle East

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • $ 2349
  • November 2018

INTRODUCTIONChronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine ...

Diabetic Foot Infection (DFI) Global Clinical Trials Review, H2, 2018

Diabetic Foot Infection (DFI) Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Diabetic Foot Infection (DFI) Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Diabetic Foot Infection (DFI) Global Clinical Trials Review, H2, 2018" provides an overview ...

Acute Heart Failure Global Clinical Trials Review, H2, 2018

Acute Heart Failure Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Acute Heart Failure Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Acute Heart Failure Global Clinical Trials Review, H2, 2018" provides an overview of Acute Heart ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on